Scinai Immunotherapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Scinai Immunotherapeutics has a total shareholder equity of $10.0M and total debt of $280.0K, which brings its debt-to-equity ratio to 2.8%. Its total assets and total liabilities are $12.3M and $2.3M respectively.
Key information
2.8%
Debt to equity ratio
US$280.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.03m |
| Equity | US$10.00m |
| Total liabilities | US$2.26m |
| Total assets | US$12.26m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2F5's short term assets ($1.6M) exceed its short term liabilities ($1.4M).
Long Term Liabilities: 2F5's short term assets ($1.6M) exceed its long term liabilities ($866.0K).
Debt to Equity History and Analysis
Debt Level: 2F5 has more cash than its total debt.
Reducing Debt: 2F5 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: 2F5's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 2F5's interest payments on its debt are well covered by EBIT.